Adam M. Brufsky, MD, PhD

The addition of tucatinib to ado-trastuzumab emtansine significantly improved PFS among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, according to study findings.

Younger postmenopausal women who underwent treatment without radiotherapy for early-stage hormone receptor-positive breast cancer experienced low 5-year recurrence rates, according to results presented at San Antonio Breast Cancer Symposium.

The addition of tucatinib to ado-trastuzumab emtansine significantly improved PFS among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, according to study findings.

SAN ANTONIO — Treatment de-escalation may be possible for patients with breast cancer who respond well to neoadjuvant chemotherapy, according to randomized phase 3 study results presented at San Antonio Breast Cancer Symposium.

MADRID — Datopotamab deruxtecan extended PFS compared with chemotherapy for patients with previously treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer, according to study results presented at ESMO Congress.

SAN ANTONIO — Residual cancer burden after neoadjuvant chemotherapy accurately predicted long-term recurrence risk and survival across all breast cancer subtypes, according to results of a meta-analysis presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Two common hormone therapy regimens had opposite long-term effects on breast cancer incidence among postmenopausal women, according to results from two large randomized controlled Women’s Health Initiative trials presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Margetuximab plus chemotherapy conferred a numerically small but statistically significant PFS and OS compared with trastuzumab plus chemotherapy for patients with relapsed or refractory HER2-positive metastatic breast cancer, according to results of a second interim analysis of the randomized phase 3 SOPHIA trial presented at San Antonio Breast Cancer Symposium.

Treatment with sacituzumab govitecan, a novel antibody-drug conjugate, resulted in objective responses among women with heavily pretreated hormone receptor-positive, HER-2-negative breast cancer, according to findings presented at the ASCO Annual Meeting.

Adam M. Brufsky, MD, PhD, professor of medicine and co-director of the Comprehensive Breast Cancer Center at the University of Pittsburgh, discusses the results of the MONARCH-2 and PALOMA-1 trials that were presented at the ASCO Annual Meeting.